semaj83/ctmatch_classification huggingface dataset:
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 17.0-65.0,  Crimean-Congo Hemorrhagic Fever Lassa Fever An individual will be enrolled in this study if the patient Meets the case definition for a probable or a suspected case of CCHF or LF (see below) Has read and signed the Informed Consent Is at least 18 years of age (17, if active military) and not greater than 65 years of age Has a blood sample drawn and a type and cross-match ordered for transfusion Agrees to collection of required specimens Agrees to report any Adverse Events, Serious and Unexpected Adverse Events for the duration of the study Agrees to a follow-up visit and to donate blood and urine specimens at day 14 (±2 days) and once between days 28 and 60 after the first dose of IV Ribavirin and to all follow-up visits for anemia or other medical conditions as required by the attending physician Woman of childbearing age must have a pregnancy test performed. If negative, she must agree not to become pregnant during treatment and for 7 months after receiving Ribavirin. She also must agree to not breast feed during treatment and for 7 months after receiving Ribavirin. Two reliable forms of effective contraception must be used including one barrier method during treatment and during the 7 month post-treatment period. She will be counseled concerning the risks of IV Ribavirin versus no treatment if the pregnancy test is positive Man agrees not to have intercourse with pregnant woman during treatment and for 7 months after receiving Ribavirin, and take precautions to avoid producing pregnancies during treatment and for 7 months after receiving Ribavirin. At least two reliable forms of effective contraception must be used including one barrier method during treatment and during the 7 month post-treatment period to avoid a pregnancy  Has known intolerance to Ribavirin Is irreversibly ill on presentation, as defined by presence of profound shock (shock which does not respond to supportive therapy within 3 hours after admission) Has hemoglobin less than 10 g/dL that cannot be corrected to 10 g/dL before initiation of IV Ribavirin Has history of hemoglobinopathies (i.e., sickle-cell anemia or thalassemia major) Has history of autoimmune hepatitis Has a calculated serum creatinine clearance of < 30 mL/min History of such as second or third degree heart block or sick sinus syndrome and without a pacemaker and no capability of a pacemaker placement or Wolfe-Parkinson-White Syndrome A sinus bradycardia of less than 40 beats per minute Is currently being treated with Didanosine (ddI). ddI must be discontinued before starting IV Ribavirin Relative
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 0.115-45.0,  Typhoid Fever Main Subjects belonging to 4 age groups will be enrolled into the trial: adults (18 to 45 years of age), children (24 to 59 months of age), older infants (9 to 12 months of age at enrollment) and infants (6 weeks of age at enrolment) Written informed consent will be obtained by the all subjects or their parents/ guardians (depending on the age group) before enrollment into the trial Only females with a negative pregnancy test and willing to participate in family planning consultations (organized by the site study team) will be allowed to participate to the trial Infants who have been vaccinated with 1 dose of BCG, HBV and OPV at birth can be enrolled into the trial, while infants who have received DTwP+HBV+Hib or OPV due at 6 weeks of age as per local EPI schedule cannot be enrolled into the trial
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 1.0-1.083,  Dengue Dengue Hemorrhagic Fever Yellow Fever Aged 12 to 13 months on the day of inclusion Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg as reported by the parent/legally acceptable representative Subject in good health, based on medical history and physical examination Subject has completed his/her vaccination schedule according to the official immunization calendar of Colombia and/or Peru, respectively Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by 2 independent witnesses if required by local regulations) Subject and parent/legally acceptable representative/tutor able to attend all scheduled visits and to comply with all trial procedures  Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination Planned participation in another clinical trial during the present trial period Planned receipt of any vaccine in the 4 weeks following first trial vaccination Previous vaccination against yellow fever (YF), hepatitis A, or measles, mumps and rubella Receipt of blood or blood-derived products in the past 3 months which might interfere with assessment of the immune response Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 weeks or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) Personal known seropositivity for human immunodeficiency virus (HIV) as reported by the parent/legally acceptable representative History of previous maternal vaccination against YF as reported by the parent/legally acceptable representative Personal history of YF or dengue infection/disease as reported by the parent/legally acceptable representative Known systemic hypersensitivity to any of the vaccine components of the vaccines that will be used in the trial, or history of a life-threatening reaction to the vaccines used in the trial or to vaccines containing any of the same substances
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Chikungunya Virus Vaccines, Virus-like Particles Viral Vaccines Humoral Immunity Chikungunya Fever A participant must meet all of the following < TAB> 18 to 50 years old < TAB> Available for clinical follow-up through Week 44 < TAB> Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process < TAB> Complete an Assessment of Understanding prior to enrollment and verbalize understanding of all questions answered incorrectly < TAB> Able and willing to complete the informed consent process < TAB> Willing to donate blood for sample storage to be used for future research < TAB> In good general health, with a BMI less than or equal to 40, without clinically significant medical history, and has satisfactorily completed screening < TAB> Physical examination and laboratory results without clinically significant findings within the 56 days prior to enrollment Laboratory within 56 days prior to enrollment  A participant will be excluded if one or more of the following conditions apply Female-Specific < TAB> Woman who is breast-feeding or planning to become pregnant during the time projected for individual study participation < TAB> Systemic immunosuppressive medications or cytotoxic medications within 12 weeks prior to enrollment [with the exceptions that a short course of corticosteroids (less than or equal to10 days duration or a single injection) for a self-limited condition at least 2 weeks prior to enrollment will not study participation] < TAB> Blood products within 16 weeks prior to enrollment < TAB> Immunoglobulin within 8 weeks prior to enrollment < TAB> Prior vaccinations with an investigational CHIKV vaccine < TAB> Investigational research agents within 4 weeks prior to enrollment < TAB> Live attenuated vaccines within 4 weeks prior to enrollment < TAB> Medically indicated subunit or killed vaccines, e.g. influenza, pneumococcal, or allergy treatment with antigen injections, within 2 weeks prior to enrollment
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Dengue Disease Dengue Fever Male or female age 18 to 50 (inclusive) years old at the time of enrollment Have negative anti-dengue, Japanese encephalitis, West Nile, and yellow fever ELISA serological tests Be informed of the nature of the study and provide written informed consent If the subject is of child-producing potential, he/she agrees to practice adequate birth control or abstain from sex Have access to the WRAIR Clinical Trials for at least 270 days, and be willing to refrain from participation in other investigational clinical trials Be in good general health  -Subjects meeting any of the following will be excluded from the study History of Flavivirus infection or history of Flavivirus vaccine (experimental or licensed product) including Japanese encephalitis, yellow fever, and dengue Have a known or suspected hypersensitivity or adverse reaction to vaccines including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain Have received a live-attenuated vaccine within 42 days prior to the initial injection on Day 0 or a subunit or killed vaccine within 30 days of the initial injection on Day 0 Have a positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or HIV antibody Are pregnant or breastfeeding Have donated or received blood, blood products, or plasma within 30 days prior to Day 0 Have any acute illness, including an oral body temperature >100.4°F, within 7 days before the initial injection on Day 0 Have a past or current history of malignant disease except for adequately treated skin cancer Exclusions but are not limited to conditions pertaining to or evidence of immunodeficiency; allergies requiring treatment with antigen injections; autoimmune disease; severe migraine headaches; unstable asthma; clinically significant cardiac arrhythmias, diabetes mellitus, thyroid disease, a bleeding disorder or a seizure disorder
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 11.0-17.0,  Immunization Rate Age 11-17 years old Active patient (visit in last 2 years) of clinics in study Need one or more vaccines or well-care visit  Up to date on vaccines and well-care
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Pneumococcal Vaccines Pneumococcal Conjugate Vaccine Healthy Japanese male and female adults aged 65 years old and older at time of enrollment. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 12 weeks before receipt of the study vaccine, are eligible Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study or for at least 28 days after the last dose of the study vaccine whichever is longer  History of severe adverse reaction including hypersensitivity such as anaphylaxis associated with a vaccine or vaccine component Previous vaccination with any licensed or experimental pneumococcal vaccine Documented Streptococcus pneumoniae infection within the past 5 years Residence in a nursing home, long-term care facility, or other institution or requirement of semiskilled nursing care
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 1.0-14.0,  Japanese Encephalitis Children aged between 1 and 14 years who had clinically diagnosed encephalitis on the basis of history of fever that lasted less than 14 days, altered consciousness with or without a history of new onset seizures with CSF finding of white cell count less than 1000 cells/mm3 with no organisms on Gram stain and a CSF: plasma glucose ratio > 40% admitted in Kanti Children's Hospital and BP Koirala Institute of Health Sciences, Nepal  Asexual Plasmodium falciparum parasites in blood Coma appears secondary to other systemic condition, eg hepatic failure, cardiac failure, toxins Patients who have documented antibiotic treatment before admission and in whom partially treated bacterial meningitis appears more likely than encephalitis Children with simple febrile convulsions, defined as a single seizure lasting less than 15 minutes followed by full recovery of consciousness within 60 minutes Pregnant or breastfeeding females Children with a GCS of 3/15, who were receiving artificial ventilation without signs of spontaneous respiration, and with absent oculocephalic reflex
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 7.0-16.0,  Dengue Dengue Fever Dengue Hemorrhagic Fever Ongoing participation in study CYD23 at the time of enrollment Assent form has been signed and dated by the subject (for subjects ≥ 7 years old), and informed consent form has been signed and dated by the parent(s) or another legally acceptable representative and by 2 independent witnesses Subject and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all study procedures  Planned participation in another dengue clinical trial during the present study Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetic Foot Ulcer Infection Non-hospitalized subjects with Type 1 or Type 2 diabetes mellitus as defined by the American Diabetes Association diagnostic (ADA, 2010). Diabetes may be treated with insulin, oral hypoglycemic agents, diet, or a combination of these therapies. Subjects whose diabetes is considered "controlled" by diet or medication in the opinion of the physician Males or females at least 18 years old Subjects must be considered by the investigator to be reliable, willing and able to give signed informed consent, and must sign the informed consent form Subjects must have a full thickness (i.e., extending through dermis but not involving tendon, bone, or joint capsule) ulcer on the foot distal to the malleoli with a surface area ≥1 cm2 after the wound has undergone appropriate debridement. Subjects must have localized mild infection of the ulcer, as defined by the IDSA as per Appendix C, with in the PGN1300 Protocol, which the investigator believes would ordinarily be treated on an outpatient basis IDSA mild infection of an ulcer is defined as The presence of ≥2 of the following items Local swelling or induration Erythema Local tenderness or pain Local warmth  Subjects with IDSA-defined moderate infection as per Appendix C, including cellulitis extending > 2 cm; lymphangitis; spread beneath the fascia; deep tissue abscess; osteomyelitis; gangrene; muscle, joint, or bone involvement Subjects with IDSA-defined severe infection as per Appendix C, within PGN1300 Protocol including systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, hyperglycemia, or azotemia) Subjects with systemic inflammatory response signs, as manifested by ≥2 of the following  Temperature >38°C or <36°C Heart rate >90 beats/min Respiratory rate >20 breaths/min or PaCO2 <32 mm Hg White blood cell count >12 000 or <4000 cells/μL or ≥10% immature (band) forms Subjects with local wound complications (e.g., prosthetic materials) Subjects currently receiving antibiotic treatment for a localized infection of the study ulcer and whose infection is improving in response to treatment Subjects requiring concurrent systemic antimicrobials during the study period for any infection, including diabetic foot ulcer
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 14.0-17.0,  Overweight Adolescent Behavior Family Research Weight Loss Adolescent ages 14-17 years old living at home with at least one parent/guardian BMI ≥ 85th percentile assent from adolescent consent from a parent/guardian willingness of one parent/guardian living with adolescent to participate in the study English speaking  Adolescent BMI ≥ 40 (requires additional medical attention the intervention is unable to provide) previously diagnosed type 1 or type 2 diabetes blood pressure in the range of stage 2 hypertension which requires medication treatment which interferes with outcomes related to blood pressure and glucose medications that significantly interfere with weight gain such as oral steroid use greater than two consecutive weeks antipsychotic medications participation in a standardized weight loss program within the previous 6 months inability to provide informed assent no parent/guardian consent insufficient reading ability to comprehend the self-administered assessment instruments (approximately 5th grade reading level)
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 0.25-16.0,  Dengue Disease Progression Age >3 months and <16 years Clinical suspicion of dengue hemorrhagic fever. (Revised WHO Classification System) Not a prisoner or ward of the state Parents able and willing to give consent. Children older then 7 able and willing to give assent  Allergic to Ultrasound gel Prisoners or wards of the state Unstable patients Known pleural effusion, ascites, or gallbladder wall thickening
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Infected by Chikungunya Virus Age at onset of symptoms ≥ 45 years Seen in consultation at the University Hospital of Fort-de-France Suspected chikungunya infection (fever and sudden onset of joint pain affecting the wrists, hands, ankles or knees) Duration of symptoms suggestive of infection chikungunya less than or equal to 10 days Presence of joint pain on the day of No history of inflammatory arthritis Absence of steroidal or non-steroidal anti-inflammatory drugs taken within two weeks prior to Ability to participate in the study throughout its duration (12 months) Patient affiliated or beneficiary of a social health care Acceptance to participate in the study and monitoring proposed and signed informed consent  Age at onset of symptoms <45 years Duration of symptoms suggestive of chikungunya for more than 10 days Lack of joint pain on the day of History of inflammatory arthritis Nonsteroidal anti-inflammatory drugs or Taking in the two weeks preceding the Inability to participate in the study throughout its duration (12 months) Patient is not affiliated or beneficiary of a social health care Refusal to participate in the study or to sign a consent
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Influenza clinical presentation that suggest influenza virus infection, including sudden onset of high fever, cough, headache, muscle and joint pain, severe malaise, sore throat and runny nose positive to influenza virus by PCR test anti viral treatment was indicated  Immune compromised patients: patients after solid organ transplant, post bone marrow transplantation, with inherited or acquired immune deficiency, or patients treated chronically with immunosuppressive drugs Pregnant women Patients who were treated with oseltamivir in the previous 6 months
Patient description: An 18-year-old male returning from a recent vacation in Asia presents to the ER with a sudden onset of high fever, chills, facial flushing, epistaxis and severe headache and joint pain. His complete blood count reveals leukopenia, increased hematocrit concentration and thrombocytopenia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Dengue Fever Stage 1 Discharge diagnosis with International Classification of Disease (ICD) code A90 A99 Availability of minimal dataset (name, IC, age, sex, diagnosis, date admit, date discharge, discharge status) Stage 2 Laboratory confirmed dengue (Non-structural 1 antigen, dengue IgM, high-titre dengue IgG, and dengue polymerase chain reaction (PCR) positive)